Clinical trials: Degenerative Conditions, Neurologic
Parkinson Disease
Vibrotactile Coordinated Reset: A Non-invasive Treatment for Parkinson's Disease
The purpose of our study is to evaluate Vibrotactile Coordinated Reset stimulation (vCR) and its effects on motor ability within Parkinson's patients. vCR will be administered with a device called the VT Brain Glove.
- Trial name
- NCT04877015
- Testing
- Active Vibrotactile Coordinated Reset (vCR)
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Synergic Medical Technologies, Inc.
Parkinson's Disease (PD)
Effect of BIA 9-1067 on the Pharmacokinetics and Pharmacodynamics of Warfarin
The purpose of this study is to investigate CYP2C9 inhibition by BIA 9-1067 through the assessment of its effect on the pharmacokinetics of S-warfarin, a substrate of CYP2C9.
- Trial name
- NCT02169440
- Testing
- BIA 9-1067, Warfarin
- Where
- Portugal
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Alzheimer's Disease, Mild Cognitive Impairment
Trial of Novel Oral Zinc Cysteine Preparation in Alzheimer's Disease
This trial aims to test the hypothesis that 1) a single dose of zinc cysteine in a proprietary gastro-retentive form will produce sustained blood levels of zinc giving a larger bioavailable amount of zinc than an FDA approved…
- Trial name
- NCT01099332
- Testing
- Gastro-retentive zinc cysteine tablet, Tablet identical physically to active comparator containing some lactose
- Where
- 3 sites in United States
- Volunteers
- 60 people
- Sponsor
- Adeona Pharmaceuticals
Parkinson Disease, Essential Tremor
[18F] LBT-999 PET Compared to [123I]-FP/CIT SPECT to Distinguish Between Parkinson's Diseases and Essential Tremor
Clinical study to demonstrate an at least equivalent performance of a new PET molecular Imaging radiopharmaceutical named [18F] LBT-999 in brain imaging compared to the SPECT reference method named [123I]-FP-CIT to establish the…
- Trial name
- NCT04265209
- Testing
- SPECT, PET
- Where
- 16 sites in France
- Volunteers
- 152 people
- Sponsor
- GE Healthcare
Age-Related Macular Degeneration
Study of Safety and Efficacy of Brolucizumab 6 mg Dosed Every 4 Weeks Compared to Aflibercept 2 mg Dosed Every 4 Weeks in Patients With Retinal Fluid Despite Frequent Anti-VEGF Injections
This clinical study was designed to compare the safety and efficacy of brolucizumab 6 mg dosed every 4 weeks to aflibercept 2 mg dosed every 4 weeks in those neovascular age-related macular degeneration (nAMD) patients with…
- Trial name
- MERLIN (NCT03710564)
- Testing
- Brolucizumab, Aflibercept
- Where
- 61 sites in United States, Puerto Rico
- Volunteers
- 535 people
- Sponsor
- Novartis Pharmaceuticals
Parkinson Disease
A Study to Assess the Safety and Effectiveness of Pridopidine Compared to Placebo in the Treatment of Levodopa-Induced Dyskinesia in Patients With Parkinson's Disease
This is a multicenter, randomized, three-arm, parallel-group, double-blind, placebo-controlled, study to evaluate the efficacy, safety and pharmacokinetics (PK) of pridopidine vs.
- Trial name
- NCT03922711
- Testing
- Pridopidine
- Where
- 33 sites in United States
- Volunteers
- 23 people
- Sponsor
- Prilenia
Amyotrophic Lateral Sclerosis
Study to Assess the Effects of PTC857 Treatment in Participants With Amyotrophic Lateral Sclerosis ALS
This study will assess the efficacy and safety of PTC857 treatment in participants diagnosed with ALS.
- Trial name
- CARDINALS (NCT05349721)
- Testing
- PTC857
- Where
- 55 sites in United States, Argentina and 11 more
- Volunteers
- 336 people
- Sponsor
- PTC Therapeutics
Healthy, Adult
Study Evaluating Effects of SAM-531 on Sleep Electroencephalogram (EEG) and Quantitative Wake EEG in Healthy Subjects
Primary: To evaluate the pharmacologic effect of single doses of SAM-531 on sleep EEG in healthy subjects.
- Trial name
- NCT00519298
- Testing
- SAM-531, Donepezil
- Where
- France
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Transthyretin (TTR) Amyloid Cardiomyopathy
Vyndaqel Capsules Special Investigation (ATTR-CM)
Secondary Data Collection : To confirm the safety and effectiveness profiles under the actual medical practice of Vyndaqel in Japan.
- Trial name
- NCT04108091
- Testing
- Treatment for TTR amyloidosis
- Where
- Japan
- Volunteers
- 1,214 people
- Sponsor
- Pfizer
Alzheimer's Disease, Mild Cognitive Impairment
Performance of AclarusDx™, a Blood-Based Transcriptomic Test for AD, in US Patients Newly Referred to a Memory Center
The purpose of this study is to assess the performance of AclarusDx™, an investigational blood test detecting gene expression information, and intended to help physicians in making an Alzheimer's Disease diagnosis in patients…
- Conditions
- Alzheimer's Disease, Mild Cognitive Impairment, Vascular Dementia, Fronto-temporal Dementia
- Trial name
- NCT01465360
- Where
- 3 sites in United States
- Volunteers
- 160 people
- Sponsor
- Exonhit
Friedreich's Ataxia
Long-Term Efficacy Study of Vatiquinone for the Treatment of Friedreich's Ataxia (FA)
The purpose of this study is to confirm the treatment effects of vatiquinone on the key measures of FA disease progression.
- Trial name
- PROVE-FA (NCT07681713)
- Testing
- Vatiquinone
- Where
- 9 sites in United States, Belgium and 4 more
- Volunteers
- 120 people
- Sponsor
- PTC Therapeutics
Progressive Supranuclear Palsy
Safety, Tolerability, and Pharmacokinetics of C2N-8E12 in Subjects With Progressive Supranuclear Palsy
This study will evaluate the safety and tolerability (maximum tolerated dose (MTD) within the specified dosing range) of single intravenous (IV) infusion of C2N-8E12 in patients with progressive supranuclear palsy (PSP).
- Trial name
- NCT02494024
- Testing
- Single dose C2N-8E12
- Where
- 12 sites in United States
- Volunteers
- 32 people
- Sponsor
- C2N Diagnostics
Parkinson Disease, Parkinson's Disease and Parkinsonism
STEM-PD Open Label Extension (OLE)
This study seeks to establish the safety and efficacy of extended twice daily time-varying caloric vestibular stimulation treatments for treating symptoms associated with Parkinson's disease.
- Trial name
- NCT04799418
- Testing
- Open Label Extension Study
- Where
- 15 sites in United States
- Volunteers
- 148 people
- Sponsor
- Scion NeuroStim
Parkinson Disease
Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations (TEMPO-3)
The purpose of this study is to assess the effect of tavapadon on the change from baseline in total daily hours of "on" time without troublesome dyskinesia in L-Dopa-treated participants with Parkinson's Disease (PD) who are…
- Trial name
- NCT04542499
- Testing
- Tavapadon
- Where
- 146 sites in United States, Australia and 12 more
- Volunteers
- 507 people
- Sponsor
- AbbVie
Low Back Pain
A Study of Tanezumab in Adults With Chronic Low Back Pain
The purpose of this study is to evaluate the efficacy and safety of multiple doses of tanezumab administered every 8 weeks in treating chronic low back pain.
- Trial name
- NCT00876187
- Testing
- Tanezumab 20 mg IV, Tanezumab 10 mg IV, Tanezumab 5 mg IV
- Where
- 135 sites in United States
- Volunteers
- 1,359 people
- Sponsor
- Pfizer
Parkinson Disease
A Clinical Study Trial of Phenlarmide in China
1. To evaluate the tolerance and safety of FLA tablets in healthy volunteers. 2. To evaluate the pharmacokinetics of FLA tablets in healthy volunteers. 3. Provide basis for dosage setting for follow-up clinical research.
- Trial name
- NCT04164121
- Testing
- Phenlarmide Tablets
- Where
- China
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Yiling Pharmaceutical Inc.
Parkinson's Disease
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066
This is a study to compare the efficacy of IPX066 and CLE in subjects with advanced Parkinson's disease.
- Trial name
- NCT01130493
- Testing
- IPX066, CLE
- Where
- 24 sites in United States, France and 2 more
- Volunteers
- 110 people
- Sponsor
- Impax Laboratories, LLC
Amyotrophic Lateral Sclerosis
Clinical Trial of Glatiramer Acetate in Amyotrophic Lateral Sclerosis (ALS)
Teva is developing 40 mg/ml Glatiramer Acetate (GA) Injection , administered once daily under the skin, for the treatment of ALS.
- Trial name
- NCT00326625
- Testing
- 40 mg glatiramer acetate
- Where
- 7 sites in Belgium, France and 4 more
- Volunteers
- 366 people
- Sponsor
- Teva Pharmaceutical Industries, Ltd.
Muscular Atrophy, Spinal
A Study of Dosing Patterns and Costs in Patients With Spinal Muscular Atrophy Receiving Disease Modifying Therapies
The aim of this study was to assess real-world dosing patterns, long-term healthcare costs, and characteristics of SMA patients who received treatment with DMTs. DMTs included onasemnogene abeparvovec, nusinersen, and risdiplam.
- Trial name
- NCT07378943
- Where
- United States
- Volunteers
- 4,114 people
- Sponsor
- Novartis Pharmaceuticals
Alzheimer Disease, Alzheimer's Disease (Incl Subtypes)
Amyloid Prediction in Early Stage Alzheimer's Disease Through Speech Phenotyping - PAST Extension
The primary objective of the study is to evaluate whether a set of algorithms analysing acoustic and linguistic patterns of speech can detect amyloid-specific cognitive impairment in early stage Alzheimer's disease, based on…
- Conditions
- Alzheimer Disease, Alzheimer's Disease (Incl Subtypes), Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease
- Trial name
- PAST-US (NCT04937959)
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Novoic Limited
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.